About Proclara Biosciences

Proclara is pioneering a new approach to treating neurodegenerative diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by Alzheimer’s, Parkinson’s, orphan peripheral amyloidosis, and other diseases caused by protein misfolding. Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.

 

Management Team

 
 

Investors & Partners

Current Investors

Private Investors

In addition to Merieux and Shire, Proclara has received funding from private life sciences investors from Europe and the US.

 

Current Partners

We are actively forging strategic partnerships to accelerate the development of our novel therapies for patients with protein misfolding diseases.

Companies interested in exploring partnering opportunities should contact bd@proclarabio.com.

 
 

Research Partnerships

MNI-01.png
RAMOT-01.png
 

Clinical Partnerships


ManUfacturing partnerships